Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for Radiodermatitis associated to radiotherapy, as well as in phase 2a clinical trial for ulcerative colitis. The company also develops Pantoprazole Magnesium for the treatment of gastric reflux; Cleo-35 for the treatment of hormonal acne in women; Dexlansoprazole; R-Spinasome anti-aging cream, serum, and regenerating creams; and anti-aging products, including day, night, and eye creams under the Purgenesis name. Devonian Health Group Inc. is headquartered in Québec, Canada.
Metrics to compare | GSD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGSDPeersSector | |
---|---|---|---|---|
P/E Ratio | −5.7x | −0.1x | −0.5x | |
PEG Ratio | 0.24 | 0.00 | 0.00 | |
Price/Book | 2.8x | 0.7x | 2.6x | |
Price / LTM Sales | 0.8x | 0.7x | 3.3x | |
Upside (Analyst Target) | - | 33.1% | 43.5% | |
Fair Value Upside | Unlock | 17.5% | 6.8% | Unlock |